The KPNA3 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-generated polyclonal knockout population derived from HeLa cells, featuring disruption of the KPNA3 gene to establish a loss-of-function model. This heterogeneous cell pool contains a spectrum of gene-editing events that collectively eliminate KPNA3 expression, providing a robust platform for studying population-level effects without clonal selection bias.
HeLa is an HPV18-positive cervical adenocarcinoma cell line widely employed in cancer and virology research. Its immortalized nature and expression of viral oncoproteins E6 and E7 make it a relevant model for examining nuclear transport dynamics within the context of HPV-driven transformation and tumor cell biology.
KPNA3 is a classical nuclear import adaptor that binds NLS-containing cargo and partners with importin beta (KPNB1) to translocate through the nuclear pore complex. Cargo release is triggered by RanGTP binding to importin beta in the nucleus. Upstream regulators of KPNA3 include E2F transcription factors, stress kinases, and p53, while its downstream cargoes encompass NF-??B (p65), p53, c-Fos, and the HPV E6/E7 oncoproteins. This positions KPNA3 as an integrator of signals controlling proliferation, stress responses, and viral pathogenesis.
In HeLa cells, KPNA3 knockout profoundly disrupts the nuclear import of p53 and NF-??B, thereby impairing tumor suppressor and survival signaling. Additionally, altered localization of HPV E6/E7 proteins may attenuate viral oncogenic functions. These effects underscore the model’s utility for dissecting KPNA3??s contribution to cervical carcinoma progression and HPV-host interplay.
Applications include nuclear transport signaling studies, HPV interaction analyses, and nuclear import inhibitor screening. Typical assays comprise Western blotting, immunofluorescence for cargo localization, NF-??B luciferase reporters, RNA-seq, co-immunoprecipitation, and viral titer quantification. For more information or application support, please contact Ascent Research.
